ORMP, US68403P2039

Oramed Pharmaceuticals stock fell 3.74 percent as targets rose

Published on 10/07/2026 at 07:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fintel set Oramed's average one-year target at USD 7.14 on September 15, 2026, up from USD 6.38. The Nasdaq quote reached USD 4.38 on October 6.

ORMP, US68403P2039, Illustration mit AI erstellt.

Oramed Pharmaceuticals stock (ISIN US68403P2039) fell 3.74 percent to USD 4.38 on Nasdaq on October 6, 2026, at 4:00 p.m. ET. The move puts the biotechnology company below the average analyst target of USD 7.14 reported by Fintel on September 15, 2026.

Targets moved higher in September

Fintel said the average one-year target rose from USD 6.38 to USD 7.14, a 12.00 percent increase. The latest target range ran from USD 7.07 to USD 7.35, leaving the average target 62.99 percent above the October 6 price of USD 4.38.

The target revision is a forward-looking analyst measure rather than company guidance. Fintel also reported Q2 2026 actual EPS of USD 1.84 against an estimated USD 0.4386, a positive surprise of 319.52 percent.

Quarterly figures show a sharp EPS swing

The Q2 2026 EPS figure stands out because Oramed's revenue was reported at USD 0.00 for the same period by Fintel. That combination makes the earnings comparison dependent on the composition of the quarter's result rather than on sales growth.

MarketBeat reported on October 2, 2026, that CFO Avraham Gabay sold 20,000 shares at an average price of USD 4.51 for USD 90,200. The same report described a consensus Hold rating based on one analyst and cited quarterly EPS of negative USD 0.09 against a USD 0.43 estimate, which differs from Fintel's Q2 2026 figures.

Oramed develops oral therapies

Oramed is developing orally administered treatments designed to deliver therapeutic proteins and peptides, including oral insulin and an oral GLP-1 candidate. The company describes this platform as a way to address medicines traditionally delivered by injection.

An investor letter dated June 25, 2026, available from Oramed Pharmaceuticals, highlighted inclusion in the Russell 2000 and Russell 3000 indexes, repayment of a Scilex loan and a strengthened balance sheet.

Stock trades below analyst target

Oramed Pharmaceuticals stock was last at USD 4.38 on Nasdaq on October 6, 2026, down USD 0.17 or 3.74 percent for the session. Its market capitalization was USD 179.3 million on the same date.